Exelixis, Inc. is a commercially successful, oncology-focused biotechnology company that strives to accelerate the discovery, development and commercialization of new medicines for difficult-to-treat cancers. With targeted business development and internal drug discovery, we aim to deliver the next generation of Exelixis medicines and help patients recover stronger and live longer.